Related Experiment Video

Updated: Aug 7, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology

G C Prendergast1

  • 1The Wistar Institute, Philadelphia, PA, USA. george.c.prendergast@dupontpharma.com

Histology and Histopathology
|February 24, 2001
PubMed

Insights

Farnesyl-transferase inhibitors (FTIs) combat cancer by targeting RhoB, a protein crucial for malignant cell function but not normal cell growth. This discovery offers new therapeutic strategies for neoplastic diseases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Identifying selective targets for cancer therapy is a key goal in neoplastic pathophysiology research.
  • Farnesyl-transferase inhibitors (FTIs) are a novel class of chemotherapeutics that inhibit or reverse malignant cell phenotypes with minimal impact on normal cells.
  • FTIs were initially developed to inhibit oncogenic Ras, a protein dependent on farnesylation for its activity.

Purpose of the Study:

  • To investigate the mechanism underlying the antineoplastic effects of Farnesyl-transferase inhibitors (FTIs).
  • To determine if the anti-cancer activity of FTIs is linked to Ras inhibition or other cellular functions.
  • To explore the role of RhoB, a small GTPase, in mediating the effects of FTIs.

Main Methods:

  • The study investigated the effects of Farnesyl-transferase inhibitors (FTIs) on cancer cells.
  • Researchers examined the link between FTI activity and oncogenic Ras inhibition.
  • The role of RhoB, a small GTPase regulating cytoskeletal dynamics and receptor trafficking, was assessed in relation to FTI treatment.

Main Results:

  • Antineoplastic effects of FTIs are not mediated by inhibition of oncogenic Ras.
  • FTIs alter the function of RhoB, a small GTPase involved in cytoskeletal regulation and cell surface receptor trafficking.
  • RhoB is dispensable for normal cell growth and differentiation in mice, highlighting its selective role in cancer.

Conclusions:

  • The antineoplastic effects of FTIs are primarily mediated through the alteration of RhoB, not Ras inhibition.
  • RhoB represents a crucial target for controlling malignant phenotypes, as it is unnecessary for normal cell physiology.
  • This research identifies a selective cellular function critical for cancer control, paving the way for novel therapeutic strategies.

More Related Videos

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...